Pharma Mar, S.A.
PHMMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -6.75 | -0.51 | -0.34 |
| FCF Yield | -0.69% | -3.92% | 2.52% | 1.80% |
| EV / EBITDA | 64.11 | 161.09 | 20.41 | 8.93 |
| Quality | ||||
| ROIC | 5.09% | 0.46% | 15.99% | 30.48% |
| Gross Margin | 95.32% | 93.92% | 93.05% | 92.85% |
| Cash Conversion Ratio | 0.50 | -11.83 | 0.88 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.79% | -11.71% | -10.07% | 38.87% |
| Free Cash Flow Growth | 67.75% | -199.77% | 64.87% | -93.52% |
| Safety | ||||
| Net Debt / EBITDA | -0.57 | -3.60 | -2.06 | -0.62 |
| Interest Coverage | 2.62 | -1.58 | 18.55 | 27.41 |
| Efficiency | ||||
| Inventory Turnover | 0.16 | 0.24 | 0.49 | 1.56 |
| Cash Conversion Cycle | 618.17 | 447.65 | 61.31 | -238.69 |